Norwegians co-operate on cancer monitoring tests:
This article was originally published in Clinica
Executive Summary
Dynal and the Norwegian National Cancer Hospital are co-operating on the development of tests to monitor the spread of cancer. Dynal, a joint venture between Dyno Industrier and AL Industrier holds exclusive rights to Dyno's microparticles for separation of cellular components.